Generic pharmaceutical company Mylan will merge with Pfizer’s off-patent medicines unit Upjohn. The new firm will be based in the US, with anticipated revenues of $19–20 billion (£15–16 billion) in 2020.
The intention is to combine Pfizer’s distribution network in China and other emerging markets with Mylan’s existing products in developed markets and future generics, but the deal does not include Pfizer’s biosimilars.
‘Upjohn has off-patent drugs like Viagra (sildenafil), Lipitor (atorvastatin) and Lyrica (pregabalin), for which Mylan has filed generic applications. This makes me wonder what happens when there is overlap between Mylan’s generics and the branded Pfizer products,’ says Josh Whitehill, a lawyer specialising in pharmaceutical and biotechnology patent law at Goodwin Procter in New York, US. ‘Do they [sell them off], or does the new company just stop selling them?’ he asks.
‘It will be interesting to see if this starts a trend of large branded drug companies selling off or spinning off their off-patent assets,’ Whitehill says. Rather than a consolidation, the deal represents a shift of Upjohn into Mylan, he states. ‘I don’t see this as disrupting the status quo, it just really is giving Mylan more legs to reach places where it couldn’t before.’
By: Rebecca Trager
Source: Chemistry World
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.